Ieq Capital LLC Has $2.45 Million Stock Position in Humana Inc. (NYSE:HUM)

Ieq Capital LLC raised its holdings in shares of Humana Inc. (NYSE:HUM) by 75.4% in the 2nd quarter, Holdings Channel.com reports. The fund owned 6,553 shares of the insurance provider’s stock after buying an additional 2,817 shares during the period. Ieq Capital LLC’s holdings in Humana were worth $2,448,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the business. Mendota Financial Group LLC increased its stake in Humana by 9.2% in the 2nd quarter. Mendota Financial Group LLC now owns 319 shares of the insurance provider’s stock valued at $119,000 after buying an additional 27 shares during the last quarter. Aurora Investment Counsel increased its position in shares of Humana by 1.3% in the fourth quarter. Aurora Investment Counsel now owns 2,273 shares of the insurance provider’s stock valued at $1,155,000 after acquiring an additional 29 shares during the last quarter. Capital Advisors Ltd. LLC raised its holdings in Humana by 17.0% during the second quarter. Capital Advisors Ltd. LLC now owns 213 shares of the insurance provider’s stock worth $80,000 after acquiring an additional 31 shares in the last quarter. EP Wealth Advisors LLC boosted its position in Humana by 1.6% during the fourth quarter. EP Wealth Advisors LLC now owns 2,294 shares of the insurance provider’s stock valued at $1,050,000 after purchasing an additional 37 shares during the last quarter. Finally, CarsonAllaria Wealth Management Ltd. grew its stake in Humana by 111.4% in the second quarter. CarsonAllaria Wealth Management Ltd. now owns 74 shares of the insurance provider’s stock valued at $28,000 after purchasing an additional 39 shares in the last quarter. Institutional investors own 92.38% of the company’s stock.

Humana Stock Performance

NYSE HUM opened at $310.41 on Friday. Humana Inc. has a 1 year low of $298.61 and a 1 year high of $530.54. The firm has a market capitalization of $37.40 billion, a price-to-earnings ratio of 19.33, a P/E/G ratio of 2.56 and a beta of 0.50. The company has a current ratio of 1.66, a quick ratio of 1.66 and a debt-to-equity ratio of 0.70. The firm’s 50 day simple moving average is $357.71 and its 200 day simple moving average is $345.61.

Humana (NYSE:HUM) last issued its quarterly earnings results on Wednesday, July 31st. The insurance provider reported $6.96 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.89 by $1.07. Humana had a return on equity of 16.12% and a net margin of 1.53%. The company had revenue of $29.54 billion for the quarter, compared to analyst estimates of $28.52 billion. During the same quarter last year, the company posted $8.94 EPS. The company’s revenue for the quarter was up 10.4% compared to the same quarter last year. As a group, research analysts expect that Humana Inc. will post 16 earnings per share for the current fiscal year.

Humana Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Monday, September 30th will be paid a $0.885 dividend. The ex-dividend date is Monday, September 30th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.14%. Humana’s payout ratio is currently 22.04%.

Wall Street Analyst Weigh In

Several research firms have recently commented on HUM. Cantor Fitzgerald reissued a “neutral” rating and issued a $395.00 price objective on shares of Humana in a report on Friday. Robert W. Baird started coverage on shares of Humana in a research note on Thursday, May 30th. They issued a “neutral” rating and a $374.00 target price for the company. Morgan Stanley assumed coverage on Humana in a report on Monday, June 24th. They set an “equal weight” rating and a $374.00 price target for the company. Truist Financial upped their price objective on Humana from $355.00 to $400.00 and gave the company a “hold” rating in a research note on Monday, July 15th. Finally, TD Cowen lifted their target price on Humana from $396.00 to $407.00 and gave the stock a “buy” rating in a research note on Wednesday, July 24th. Thirteen equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $398.70.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.